Novo Nordisk A/S: Novo Nordisk achieves primary objectives of ONWARDS 3 and 4 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin degludec in ONWARDS 3
Bagsværd, Denmark, 29 July 2022 - Novo Nordisk today announced headline results from the ONWARDS 3 and ONWARDS 4 phase 3a trials with once-weekly insulin icodec in adults with type 2 diabetes. ONWARDS
Ambre Brown Morley Martin Holst Lange Daniel Muusmann Bohsen Natalia Salomao Abrahao David Heiberg Landsted Novo Nordisk
Source: finanznachrichten.de